chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient reported burning sensation shortly, ~10 minutes,  after receiving vaccine that carried across back of shoulder.  Patient reported feeling "loopy/drunk".  Patient refused all treatment and EMS.  Around 40 minutes or so, patient vomited.  Patient left with friends an hour after vaccine given.
This spontaneous case reported by a consumer, describes the occurrence of pyrexia (mild fever), chills and headache in a female patient, of an unknown age, who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 002A21A) for COVID-19 immunization. No medical history reported. On Feb 6, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On Mar 3, 2021, received the second dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On Mar 4, 2021, patient experienced pyrexia (mild fever), chills and headache. The patient treated with Tylenol (paracetamol) for headache, 1 dosage form. At the time of the report, pyrexia (mild fever), chills and headache resolved. Patient stated she had reactive lymph nodes. No concomitant medications reported. This case linked to MOD-2021-035328 (patient link). Most recent follow-up information incorporated above included: On Apr 30, 2021: Event resolved.
My grandmother had transient very high blood pressure for a few days about three weeks after vaccination. She always has really low BP because her thyroid is a little low and she's always had very low bp like 110/80. But for a couple days her bp was 156/80 and gradually went back down. I'm reporting this, because my mother-in-law had the exact same bp and experience about three weeks after the second dose. While transient, I think if this represents a trend, they should monitor at least the elderly for bp spikes a few weeks after the shot, just to make sure they don't have a stroke. I'll report my mother-in-law's experience next, she's almost the same age.
devel chickenpox on 1DEC97;many lesions on back, chest & abd-some in mouth & hair;no adverse rxn;had recv varivax on 21JUn96;
Due to 4 days progressive worsen skin lesion. Lesion as erythema multiform, generalized on hand, forearm, body and lower leg; Oral ulcer; Chill; Body ache; Joint pain; Joints swelling; Diarrhea; This is a spontaneous report from a contactable other healthcare professional (HCP). A 60-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EN6201), via unspecified route of administration in the left arm on 17Feb2021 as single dose for COVID-19 immunization. Medical history included hyperlipidemia. The patient had no known allergies. The patient is not pregnant. There were no vaccine in four weeks. Other medications in two weeks included cholesterol med. The previously received the first dose of BNT162B2 on 26Jan2021 12:00 intramuscular at left arm (lot number: EL9262) for COVID-19 immunization. The patient was seen at urgent care on 04Mar2021 due to 4 days progressive worsened skin lesion. Lesion as erythema multiform, generalized on hand, forearm, body and lower leg from 28Feb2021 (12:00 AM). Patient presented with chill, body ache, joint pain, joints swelling and diarrhea since second dose of vaccine on 17Feb2021. She also has oral ulcer at the same time when rash started on 28Feb2021. Vital sign was stable, no shortness of breath (SOB) and no chest pain. Events resulted in Doctor or other HCP office/clinic visit. The treatment for the events included Hydroxyzine 25 mg prn. It was unknown if patient had COVID prior vaccination or if COVID tested post vaccination. The outcome of the events was not recovered.; Sender's Comments: Based on the current available information and the plausible drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of event Erythema multiforme cannot be excluded.  The case will be reassessed if additional information becomes available.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
Patient was seen 2 days after vaccines at the after hours care for children, fever max 104 degrees Axillary.
Received ZOSTAVAX 7-11-2008; 7-18-2008 client experienced facial droop (L) side x 1 minute.  Seen by PP.  Dr. (diagnosis Bell's palsy) on 7-23-2008.  Continues to experience (L) sided facial droop lasting 1 minute when fatigued.  (L) eye twitching prior 1 month to vaccine June 2008.
Patient developed a sensitive hyperpigmented area at site of vaccines.  Was initially red, then became bruise-like and now is red/purple.  No lump felt.  Not hot.  "1"x 1/2" on left anterior thigh.
body aches; headache; fatigue; nausea; runny nose; sneezing; 99.2 fever; wheezing in the chest; This spontaneous case was reported by a patient and describes the occurrence of RHINORRHOEA (runny nose), WHEEZING (wheezing in the chest), SNEEZING (sneezing), PYREXIA (99.2 fever) and NAUSEA (nausea) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Heart failure since 15-Jan-2021, Asthma since 15-Jan-2021 and Heart attack since 15-Jan-2021. Concurrent medical conditions included Diabetes since 15-Jan-2021, Cholesterol since 15-Jan-2021, Hypertension on 15-Jan-2021 and Heart disease, unspecified since 15-Jan-2021. Concomitant products included METFORMIN , GLIMEPIRIDE, DULAGLUTIDE (TRULICITY), CARVEDILOL, LISINOPRIL, FUROSEMIDE, PRAVASTATIN, FENOFIBRATE and ACETYLSALICYLIC ACID (BABY ASPIRIN).    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced WHEEZING (wheezing in the chest). On 14-Jan-2021, the patient experienced RHINORRHOEA (runny nose), SNEEZING (sneezing) and PYREXIA (99.2 fever). On 15-Jan-2021, the patient experienced NAUSEA (nausea), HEADACHE (headache) and FATIGUE (fatigue). On an unknown date, the patient experienced MYALGIA (body aches). The patient was treated with ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 15-Jan-2021, WHEEZING (wheezing in the chest) had resolved. At the time of the report, RHINORRHOEA (runny nose), SNEEZING (sneezing), PYREXIA (99.2 fever), NAUSEA (nausea), MYALGIA (body aches), HEADACHE (headache) and FATIGUE (fatigue) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment included aspirin and Tylenol.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This spontaneous case was reported by a consumer and describes the occurrence of PAIN (All over my body hurts), CHILLS (Chills), HEADACHE (Headache), MYALGIA (Muscle pain) and ARTHRALGIA (Joint pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The patient's past medical history included No adverse event (No reported medical history). On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced PAIN (All over my body hurts), CHILLS (Chills), HEADACHE (Headache), MYALGIA (Muscle pain) and ARTHRALGIA (Joint pain). At the time of the report, PAIN (All over my body hurts), CHILLS (Chills), HEADACHE (Headache), MYALGIA (Muscle pain) and ARTHRALGIA (Joint pain) had not resolved.    The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No relevant concomitant medications were reported. Treatment details included paracetamol and melatonin.
1 week history of shortness of breath and nonproductive cough beginning shortly after receipt of second dose. Patient became hypoxic and had diffuse consolidation through left lung with wedge-shapes consolidation involving the right upper and midlateral lungs. Leukocytosis and bandemia noted and acute renal failure. Developed atrial fibrillation and rapid ventricular response. Multilobal pneumonia, septic shock, non-q-wave myocardial infarction, acute renal failure. Patient expired.
pt recv vax & devel cellulitis & was hosp following vax;no further info was available as of the date of this report;
Chills; fever; muscle aches; nausea; headache; This is a spontaneous report received from a contactable consumer or other non hcp. A 54-years-old non-pregnancy female patient received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/lot number was not reported) via an unspecified route of administration in Arm Left on 26Mar2021 at 15:00 (age at vaccination 54years old) as single dose for covid-19 immunisation. The patient was not pregnant at the time of vaccination. Medical history included hyperthyroidism from an unknown date and unknown if ongoing autoimmune disorders/allergies run in the family, drug hypersensitivity from an unknown date and unknown if ongoing, drug hypersensitivity from an unknown date and unknown if ongoing, drug hypersensitivity from an unknown date and unknown if ongoing , mycotic allergy from an unknown date and unknown if ongoing , food allergy from an unknown date and unknown if ongoing , food allergy from an unknown date and unknown if ongoing , dairy intolerance from an unknown date and unknown if ongoing. Prior to vaccination, the patient was diagnosed with COVID-19 reported as unknown. The patient did not receive any other vaccines within 4 weeks and other medications within 2 weeks prior to the COVID vaccine. The patient's concomitant medications were not reported. Since the vaccination, the patient had not been tested positive for COVID-19. On 26Mar2021 at 20:00 the patient experienced chills, fever, muscle aches, nausea, headache. The patient did not receive any treatment for the adverse events. The clinical outcome of the event was recovered on unspecified date in Mar2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
The second day, headache and nausea but went away. A knot that went away also. Has a hive that's red and hot to the touch.
Patient presented for COVID vaccine and indicated that she has had anaphylaxis but only to allergy shots in the past, not to other vaccines. Our immunizing technician gave the patient her first COVID vaccine between 2:45 and 3pm. She sat down for observation with her daughter beside her. About 10 to 15 minutes later the patient began coughing more and more profusely. She expressed chest tightness and became flush in her face and upper chest. She stated she was going to use her EpiPen that she carried with her. An in-date EpiPen from the pharmacy was provided instead and the patient self-injected in the right thigh as she was familiar with its use. She was monitored after and she continued to cough along with having some jittery feelings from the EpiPen. This continued for about 3 minutes with her still straining to cough. She wanted to hold off on the second dose of the EpiPen as she was still jittery but the paramedics were called for her. The paramedics arrived and they took over the scene and took her to the emergency room at 3:25pm.
CHILLS; FEVER; BODY ACHES; SLEPT 24 HOURS; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown, expiry: UNKNOWN) dose was not reported, administered on 12-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On MAR-2021, the subject experienced chills. On MAR-2021, the subject experienced fever. On MAR-2021, the subject experienced body aches. On MAR-2021, the subject experienced slept 24 hours. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the chills, fever, body aches and slept 24 hours was not reported. This report was non-serious.
Patient complains of painful arm (injection site) and difficult to raise and move the left arm after giving the injection. Patient applied ice and heat compress but no relief. Patient was advised to see her primary care but no one can drive her.
p/vax pt devel numbness w/in 3mo of vax;as of 10/8/99 pt had been dx w/MS; Annual FU: pain now in neck
a little tired; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (a little tired) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Apr-2021, the patient experienced FATIGUE (a little tired). At the time of the report, FATIGUE (a little tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication information provided by the reporter. No treatment information provided.   This case was linked to MOD-2022-465023, MOD-2022-465024 (Patient Link).
Per report from mom during 6mo WCC, pt had temperature of 100.5 after vaccines last time. Pt went to ER for evaluation. Upon clarification, mom stated the temperature was 105. Pt was otherwise acting normally, no other symptoms. Urine was obtained - no infection.
continual crying x 3-4days; very large local area of redness & swelling-whole thigh area fever 102;
Ringing of the ears - started after the Covid vaccine (dose #1) - thought it was at the beginning of march but really pinpointed date on 3/14/21 and has been constant since.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP).  An 84-year-old male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Other medication in 2weeks: Yes. Antiviral details: product: Paxlovid, COVID 19 Treatment, treatment start date 22Sep2022.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Severe chest pain(angina), amnesia, extreme fatigue, unable to regulate body temperature, tachycardia, and hypersomnia after administration of second Covid-19 vaccination.  Amnesia resolved within two days of injection.  Chest pain, fatigue, poor body temperature regulation, tachycardia, and hypersomnia are still present.
BODY ACHES; Flu like symptoms; PAIN IN RIGHT FOOT AND HAND; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (BODY ACHES), INFLUENZA LIKE ILLNESS (Flu like symptoms), PAIN IN EXTREMITY (PAIN IN RIGHT FOOT AND HAND) and FATIGUE (Fatigue) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On 09-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jun-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On 06-Apr-2021, the patient experienced PAIN (BODY ACHES), INFLUENZA LIKE ILLNESS (Flu like symptoms), PAIN IN EXTREMITY (PAIN IN RIGHT FOOT AND HAND) and FATIGUE (Fatigue). At the time of the report, PAIN (BODY ACHES), INFLUENZA LIKE ILLNESS (Flu like symptoms), PAIN IN EXTREMITY (PAIN IN RIGHT FOOT AND HAND) and FATIGUE (Fatigue) outcome was unknown.            No concomitant medications were reported. No treatment information was reported. It was unknown if patient was enrolled in a COVID-19 clinical trial.   Reporter did not allow further contact
Dizziness, Headache, Myalgia, night sweats, chills Narrative:
This spontaneous report was received from a 57 years old male consumer (who is also a Registered Nurse) reporting on himself who on 17-JAN-2013 was vaccinated intramuscularly with a dose of ZOSTAVAX (lot #, and dose not reported) and on the other arm at the same visit was vaccinated with a doe of diphtheria toxoid (+) pertussis vaccine (unspecified) (+) tetanus toxo (dose, lot # and route not reported). The patient said the injection was painful and he still has some soreness in the injected arm (onset date: 17-JAN-2013). Patient's outcome was unknown. The relatedness for injection site pain was unknown for ZOSTAVAX. Additional information has been requested.
Pt reported that 12 hours after receiving vaccines she started with fever HA, vomiting, diarrhea, and swelling and pain at the injection site. Unable to keep solid down. Sx continue today at OV on 11/21/08, but afebrile.
Patient became short of breath and had to take inhaler Patient states she was anxious about getting the vaccine and had not taken her morning inhaled dose before getting her vaccine Released home without any further complaints Vital signs- 97/45, 122, 24, 99% Vital Signs- 126/74, 103, 18, 99%
pt recv vax;approx 1 hr later,mom called & reported  pt c/o SOB, hives on trunk;to MD; adrenalin,dph,decadron given;w/in 5 mins sz resolved per mom;MD instructed not to take TD again;
Joint pains, wrists, shoulders knees, couldn't walk for couple days, worst symptoms lasted 48 hours. Mostly resolved 4 days later also has small blisters on R hand no fevers. Took TYLENOL.
This spontaneous report was received from a healthcare worker regarding to a patient of unknown age and gender. The patient's medical history and concurrent conditions were not reported. On 13-APR-2016, the patient was vaccinated with an improperly stored dose of VAQTA (lot # L031196, expiry date 05-FEB-2017) dosage regimen and route unknown. Concomitant medications were not reported. The vaccine was subjected to temperature excursion of 25.6 F for a time frame of 132 hours. It was reported there were no previous temperature excursion. Product quality complaint (PQC) was not filed. This report is one of the several reports received from the same reporter. Additional information has been requested.
Shortly after receiving the vaccine: lightheadedness lasting a few hours. The day after sore arm at the injection site. 3 days after until present: major fatigue.
This case was reported by a pharmacist and described the occurrence of hive in a female subject of unspecified age who was vaccinated with FLUARIX (GlaxoSmithKline). On 4 October 2011 the subject received 1st dose of FLUARIX (.5 ml, unknown, left arm); FLULAVAL was reported but the lot number of the administered vaccine corresponded to FLUARIX. On 4 October 2011, less than one day after vaccination with FLUARIX, the subject experienced hives on left arm and left hip as well as muscle aches. The subject required medical attention in which she received treatment with BENADRYL in the clinic at the hospital where she is an employee. The subject missed one day of work. At the time of reporting the hives and muscle aches were improved. The pharmacist considered the hives and muscle aches were possibly related to vaccination with FLUARIX. Follow-up information was received on 02 November 2011. It was reported that the female subject was 31 years old. She received vaccination with FLUARIX on 04 October 2011 and events of hives and muscle pain began on the same day, 04 October 2011. The events resolved on 06 October 2011.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 31-year-old male patient received BNT162b2 (BNT162B2), on 24Feb2021 as dose 1, single (Lot number: En6200), on 17Mar2021 as dose 2, single (Lot number: En6207) and on 26Oct2021 as dose 3 (booster), single (Lot number: 3203080) at the age of 31 years for covid-19 immunisation. The patient's relevant medical history included: "Reoccurring pericarditis" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing); "gerd" (unspecified if ongoing). Concomitant medication(s) included: LISINOPRIL; PANTOPRAZOLE. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 20Jul2022, outcome "not recovered" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: Blood pressure measurement: (unspecified date) High; SARS-CoV-2 test: (20Jul2022) Positive; (26Jul2022) Negative; (28Jul2022) Positive; (30Jul2022) Positive, notes: Still testing positive with head cold like symptoms on 30Jul. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Patient received Paxlovid for covid-19 treatment from 20Jul2022 to 25Jul2022.
C/o photophobia, nausea, chills/sweats, dizziness, vomited (1x only) for 2 days after smallpox vax.
crying for more than 3hrs, unconsolable was seen in hosp & discharged home;no treatment given
This spontaneous report as received from a registered nurse refers to an unspecified number of postpartum female patients. On an unknown date the patients were vaccinated with an unspecified number of doses of MMR II, dose and route of administration were not reported. No other co-suspects were reported. No concomitant medications were reported. On an unknown date the patient had titers for rubella that were low. The nurse also reported on an single patient with "equivocal" titer results who needed another vaccine dose (MARRS case # 1212USA002764, same reporter link). The outcome of low rubella titers is unknown. The relatedness for low rubella titers was not reported for MMR II. Additional information has been requested.
This is a spontaneous report from a contactable pharmacist based on information received by Pfizer from Merck & Co., Inc. (Manufacturer Control Number 00101450). A patient of unspecified age, ethnicity, and gender received PREVNAR, via an unspecified route of administration on an unspecified date at a single dose. The patient's medical history and concomitant medications were not reported. On an unknown date, the patient developed a lump at the site of pneumococcal 7-valent conjugate vaccine (diphtheria crm197 protein) injection. The clinical outcome of the event, vaccination site mass, was not recovered. No follow up attempts possible. No further information expected.